SG148034A1 - Non-neurotoxic plasminogen activating factors for treating stroke - Google Patents
Non-neurotoxic plasminogen activating factors for treating strokeInfo
- Publication number
- SG148034A1 SG148034A1 SG200604427-5A SG2006044275A SG148034A1 SG 148034 A1 SG148034 A1 SG 148034A1 SG 2006044275 A SG2006044275 A SG 2006044275A SG 148034 A1 SG148034 A1 SG 148034A1
- Authority
- SG
- Singapore
- Prior art keywords
- activating factors
- plasminogen activating
- neurotoxic plasminogen
- treating stroke
- stroke
- Prior art date
Links
- 102000013566 Plasminogen Human genes 0.000 title abstract 3
- 108010051456 Plasminogen Proteins 0.000 title abstract 3
- 230000003213 activating effect Effects 0.000 title abstract 3
- 231100000501 nonneurotoxic Toxicity 0.000 title abstract 3
- 208000006011 Stroke Diseases 0.000 abstract 3
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 241000288900 Desmodus rotundus Species 0.000 abstract 1
- ALPWRKFXEOAUDR-GKEJWYBXSA-M sodium;[(2r)-2,3-di(octadecanoyloxy)propyl] hydrogen phosphate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)([O-])=O)OC(=O)CCCCCCCCCCCCCCCCC ALPWRKFXEOAUDR-GKEJWYBXSA-M 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21068—Tissue plasminogen activator (3.4.21.68), i.e. tPA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21069—Protein C activated (3.4.21.69)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10153601A DE10153601A1 (de) | 2001-11-02 | 2001-11-02 | DSPA zur Behandlung von Schlaganfall |
EP01130006A EP1308166B1 (de) | 2001-11-02 | 2001-12-17 | Nicht-neurotoxische Plasminogen Aktivierende Faktoren zur Behandlung von Schlaganfällen |
Publications (1)
Publication Number | Publication Date |
---|---|
SG148034A1 true SG148034A1 (en) | 2008-12-31 |
Family
ID=7704253
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG200604427-5A SG148034A1 (en) | 2001-11-02 | 2002-10-31 | Non-neurotoxic plasminogen activating factors for treating stroke |
Country Status (27)
Country | Link |
---|---|
US (7) | US20050048027A1 (ko) |
EP (4) | EP1308166B1 (ko) |
JP (2) | JP5004407B2 (ko) |
KR (3) | KR20070087248A (ko) |
CN (2) | CN101156948A (ko) |
AT (3) | ATE440614T1 (ko) |
AU (1) | AU2002350660C1 (ko) |
BR (1) | BR0213856A (ko) |
CA (1) | CA2465792C (ko) |
CY (3) | CY1108446T1 (ko) |
DE (3) | DE10153601A1 (ko) |
DK (3) | DK1308166T3 (ko) |
EA (3) | EA010858B1 (ko) |
ES (3) | ES2332576T3 (ko) |
HK (1) | HK1057328A1 (ko) |
HR (1) | HRP20040383B1 (ko) |
HU (1) | HU230163B1 (ko) |
IL (1) | IL205695A0 (ko) |
MX (1) | MXPA04004155A (ko) |
NO (1) | NO329789B1 (ko) |
NZ (2) | NZ532903A (ko) |
PL (1) | PL208343B1 (ko) |
PT (3) | PT1308166E (ko) |
SG (1) | SG148034A1 (ko) |
SI (2) | SI1997510T1 (ko) |
WO (1) | WO2003037363A2 (ko) |
ZA (1) | ZA200403285B (ko) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10153601A1 (de) * | 2001-11-02 | 2003-05-22 | Paion Gmbh | DSPA zur Behandlung von Schlaganfall |
WO2004096267A1 (de) * | 2003-05-02 | 2004-11-11 | Paion Gmbh | Intravenöse injektion nicht-neurotoxischer plasminogen-aktivatoren zur behandlung von schlaganfall |
US20060135425A1 (en) * | 2003-05-02 | 2006-06-22 | Paion Deutschland Gmbh | Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke |
KR101212631B1 (ko) * | 2003-05-02 | 2012-12-14 | 하. 룬드벡 아크티에셀스카브 | 뇌졸중을 치료하기 위한 플라스미노겐 비-신경독성활성인자의 정맥내 주사 방법 |
US20080057050A1 (en) * | 2003-05-02 | 2008-03-06 | Paion Deutschland Gmbh | Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke |
AU2004237407A1 (en) * | 2003-05-05 | 2004-11-18 | Paion Deutschland Gmbh | Glutamate receptor antagonists as neuroprotectives |
DE10342518A1 (de) * | 2003-09-12 | 2005-05-12 | Paion Gmbh | Plasminogen-Aktivatoren mit verringerter Lysin-Bindungskapazität |
JP2006241109A (ja) * | 2005-03-04 | 2006-09-14 | Paion Deutschland Gmbh | ヒトPセレクチンおよびDSPAα1に対する抗体を含む融合タンパク質 |
TWI482628B (zh) * | 2007-10-18 | 2015-05-01 | Lundbeck & Co As H | 新穎之血栓溶解病患次群 |
WO2011107299A2 (en) | 2010-04-16 | 2011-09-09 | Paion Deutschland Gmbh | Method for the manufacture of recombinant dspa alpha1 |
WO2012093132A1 (en) * | 2011-01-05 | 2012-07-12 | Thrombogenics Nv | Plasminogen and plasmin variants |
CN103764163A (zh) | 2011-08-12 | 2014-04-30 | 斯路姆基因公司 | 纤溶酶原和纤溶酶变体 |
US11613744B2 (en) | 2018-12-28 | 2023-03-28 | Vertex Pharmaceuticals Incorporated | Modified urokinase-type plasminogen activator polypeptides and methods of use |
EP3902913A1 (en) * | 2018-12-28 | 2021-11-03 | Catalyst Biosciences, Inc. | Modified urokinase-type plasminogen activator polypeptides and methods of use |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4766075A (en) * | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
AR241654A1 (es) | 1982-05-05 | 1992-10-30 | Genentech Inc | Procedimiento para producir activador de plasminogeno de tejido humano. |
US5244806A (en) * | 1985-08-26 | 1993-09-14 | Eli Lilly And Company | DNA encoding novel tissue plasminogen activator derivatives having kringles 1 and 2 deleted, vectors and host cells |
DE3643158A1 (de) | 1986-04-21 | 1987-11-19 | Boehringer Mannheim Gmbh | Gewebs-plasminogen-aktivator(tpa) - derivat und seine herstellung |
JPH087179B2 (ja) * | 1986-09-27 | 1996-01-29 | 日本碍子株式会社 | ガスセンサ |
WO1988005081A2 (en) * | 1986-12-30 | 1988-07-14 | Cetus Corporation | Novel plasminogen activator |
IL87276A (en) * | 1987-08-03 | 1995-07-31 | Fujisawa Pharmaceutical Co | Analog of a tissue plasminogen activator containing the Pringle 2 and protease regions only, DNA encoding it, processes for its preparation, and pharmaceutical preparations containing it |
EP0386240B1 (en) * | 1987-10-29 | 1995-07-19 | Yamanouchi Pharmaceutical Co. Ltd. | Novel polypeptide compounds |
US5094953A (en) | 1988-03-21 | 1992-03-10 | Genentech, Inc. | Human tissue plasminogen activator variants |
DK176140B1 (da) * | 1988-07-20 | 2006-09-25 | Schering Ag Patentabteilung | Flagermusspyt-plasminogenaktivatorer |
DE3825253A1 (de) | 1988-07-25 | 1990-02-01 | Boehringer Mannheim Gmbh | T-pa-derivat und seine herstellung |
US5714145A (en) * | 1988-09-02 | 1998-02-03 | Genentech, Inc. | Tissue plasminogen activator having zymogenic or fibrin specific properties |
JPH0273774A (ja) * | 1988-09-09 | 1990-03-13 | Nec Corp | ファクシミリ装置 |
GB8901422D0 (en) * | 1989-01-23 | 1989-03-15 | Fujisawa Pharmaceutical Co | New tissue plasminogen activator |
US5676947A (en) * | 1989-02-07 | 1997-10-14 | Boehringer Manneheim Gmbh | Method for treating thromboembolic conditions using thrombolytically active proteins |
DE3903581A1 (de) * | 1989-02-07 | 1990-08-16 | Boehringer Mannheim Gmbh | Gewebs-plasminogenaktivator-derivat |
US6008019A (en) * | 1989-02-13 | 1999-12-28 | Schering Aktiengesellschaft | Plasminogen activator from saliva of the vampire bat |
DE3904580A1 (de) | 1989-02-13 | 1990-08-16 | Schering Ag | Neues thrombolytikum |
DE3917949A1 (de) * | 1989-05-30 | 1991-01-24 | Schering Ag | Neues thrombolytikum |
WO1990009438A1 (en) * | 1989-02-13 | 1990-08-23 | Schering Aktiengesellschaft Berlin Und Bergkamen | Novel thrombolytic |
DE69033653T2 (de) * | 1989-04-07 | 2001-06-07 | Cancerforskningsfonden Af 1989 | Plasminogen-aktivator-rezeptor vom urokinasetyp |
US5891664A (en) * | 1989-04-07 | 1999-04-06 | Cancerforskningsfondet Af 1989 | Vectors and methods for recombinant production of uPA-binding fragments of the human urokinase-type plasminogen receptor (uPAR) |
JPH0352119A (ja) * | 1989-07-19 | 1991-03-06 | Matsushita Electric Ind Co Ltd | 光学式記録再生装置 |
NL8902454A (nl) | 1989-10-03 | 1991-05-01 | Stichting Centraal Lab | Mutanten van de humane plasminogeen activator inhibitor 1 (pai-1), hun bereiding en toepassing, en recombinante polynucleotiden die voor deze mutanten coderende genetische informatie omvatten. |
US5326700A (en) * | 1990-11-06 | 1994-07-05 | Eli Lilly And Company | DNA sequences encoding t-PA derivatives with cleavable sites |
DE4123845A1 (de) * | 1991-07-18 | 1993-01-21 | Boehringer Mannheim Gmbh | Pharmazeutische verpackungseinheit enthaltend plasminogenaktivatoren zur mehrfachbolusgabe |
EP0580685B1 (de) | 1991-04-16 | 1996-01-03 | Roche Diagnostics GmbH | Pharmazeutische verpackungseinheit enthaltend plasminogenaktivatoren zur mehrfachbolusgabe |
US5595736A (en) * | 1991-04-22 | 1997-01-21 | Eli Lilly And Company | Compounds and methods for treatment of thromboembolic disorders |
NL9101520A (nl) * | 1991-09-09 | 1993-04-01 | Stork Fibron Bv | Werkwijze voor het vervaardigen van een eetbaar produkt. |
CA2124937C (en) | 1991-12-16 | 2001-06-05 | William F. Bennett | T-pa substitution variants with improved fibrin-specificity |
RU2183214C2 (ru) * | 1992-12-04 | 2002-06-10 | Шеринг Аг | Природный и рекомбинантный ингибиторы тромбина, их получение и применение |
US5510330A (en) * | 1994-03-25 | 1996-04-23 | Boehringer Mannheim Gmbh | Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof. |
GB9412131D0 (en) * | 1994-06-17 | 1994-08-10 | British Bio Technology | Thrombolytic composition |
DE4423574A1 (de) | 1994-07-05 | 1996-01-11 | Boehringer Mannheim Gmbh | Nicht-glykosylierte Plasminogenaktivator-Derivate und ihre Verwendung bei erhöhtem Blutungsrisiko |
US5827832A (en) * | 1995-03-06 | 1998-10-27 | Interneuron Pharmaceuticals, Inc. | Method of protecting brain tissue from cerebral infarction subsequent to ischemia |
US5786187A (en) * | 1995-09-21 | 1998-07-28 | The Research Foundation Of State University Of New York | Method for reducing neuronal degeneration associated with seizure |
US5945432A (en) * | 1995-12-22 | 1999-08-31 | The University Of Vermont And State Agricultural College | Thrombolytic agents and thienopyridine derivatives in acute stroke |
US20020081294A1 (en) * | 1996-01-23 | 2002-06-27 | Genentech, Inc. | Co-administration of a thrombolytic and an anti-CD18 antibody in stroke |
US5731186A (en) * | 1996-02-05 | 1998-03-24 | Schering Aktiengesellschaft | Method for the production of rDSPA α1 |
US6235947B1 (en) * | 1997-04-14 | 2001-05-22 | Takeda Chemical Industries, Ltd. | D-mannitol and its preparation |
US5830349A (en) * | 1996-07-22 | 1998-11-03 | Dana Corporation | Flow inverter for filters |
AU722221B2 (en) | 1996-10-01 | 2000-07-27 | American Cyanamid Company | Biological insect control agents expressing insect-specific mite toxin genes, methods and compositions |
US6008109A (en) * | 1997-12-19 | 1999-12-28 | Advanced Micro Devices, Inc. | Trench isolation structure having a low K dielectric encapsulated by oxide |
KR20010069066A (ko) * | 2000-01-12 | 2001-07-23 | 이종원 | 저산소 농도하에서 생존이 가능하도록 하는 동물세포의배양방법 |
DE10008646A1 (de) | 2000-02-24 | 2001-09-13 | Kempten Elektroschmelz Gmbh | Beschichteter Formkörper aus Siliciumnitrid |
GB0025473D0 (en) * | 2000-10-17 | 2000-11-29 | Pfizer Ltd | Pharmaceutical combinations |
US20020089179A1 (en) * | 2000-12-30 | 2002-07-11 | Levon Guyumjan | Hose coupling apparatus and method |
DE10153601A1 (de) * | 2001-11-02 | 2003-05-22 | Paion Gmbh | DSPA zur Behandlung von Schlaganfall |
WO2004096267A1 (de) | 2003-05-02 | 2004-11-11 | Paion Gmbh | Intravenöse injektion nicht-neurotoxischer plasminogen-aktivatoren zur behandlung von schlaganfall |
US20060135425A1 (en) | 2003-05-02 | 2006-06-22 | Paion Deutschland Gmbh | Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke |
US20080057050A1 (en) | 2003-05-02 | 2008-03-06 | Paion Deutschland Gmbh | Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke |
KR101212631B1 (ko) | 2003-05-02 | 2012-12-14 | 하. 룬드벡 아크티에셀스카브 | 뇌졸중을 치료하기 위한 플라스미노겐 비-신경독성활성인자의 정맥내 주사 방법 |
AU2004237407A1 (en) | 2003-05-05 | 2004-11-18 | Paion Deutschland Gmbh | Glutamate receptor antagonists as neuroprotectives |
WO2005018564A2 (en) | 2003-08-22 | 2005-03-03 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and a low-molecular-weight heparin for the treatment of central nervous system damage |
DE10342518A1 (de) | 2003-09-12 | 2005-05-12 | Paion Gmbh | Plasminogen-Aktivatoren mit verringerter Lysin-Bindungskapazität |
TWI482628B (zh) | 2007-10-18 | 2015-05-01 | Lundbeck & Co As H | 新穎之血栓溶解病患次群 |
-
2001
- 2001-11-02 DE DE10153601A patent/DE10153601A1/de not_active Ceased
- 2001-12-17 AT AT01130006T patent/ATE440614T1/de active
- 2001-12-17 DK DK01130006T patent/DK1308166T3/da active
- 2001-12-17 DE DE50115077T patent/DE50115077D1/de not_active Expired - Lifetime
- 2001-12-17 PT PT01130006T patent/PT1308166E/pt unknown
- 2001-12-17 ES ES01130006T patent/ES2332576T3/es not_active Expired - Lifetime
- 2001-12-17 EP EP01130006A patent/EP1308166B1/de not_active Expired - Lifetime
-
2002
- 2002-10-31 SI SI200230980T patent/SI1997510T1/sl unknown
- 2002-10-31 PL PL369872A patent/PL208343B1/pl unknown
- 2002-10-31 CN CNA2007101051509A patent/CN101156948A/zh active Pending
- 2002-10-31 SG SG200604427-5A patent/SG148034A1/en unknown
- 2002-10-31 AT AT02785348T patent/ATE401910T1/de active
- 2002-10-31 EA EA200400624A patent/EA010858B1/ru not_active IP Right Cessation
- 2002-10-31 WO PCT/EP2002/012204 patent/WO2003037363A2/de active Application Filing
- 2002-10-31 NZ NZ532903A patent/NZ532903A/en not_active IP Right Cessation
- 2002-10-31 KR KR1020077017712A patent/KR20070087248A/ko active Application Filing
- 2002-10-31 CA CA2465792A patent/CA2465792C/en not_active Expired - Fee Related
- 2002-10-31 DE DE50212548T patent/DE50212548D1/de not_active Expired - Lifetime
- 2002-10-31 ES ES08012976T patent/ES2382224T3/es not_active Expired - Lifetime
- 2002-10-31 EA EA200801714A patent/EA013707B1/ru not_active IP Right Cessation
- 2002-10-31 US US10/494,004 patent/US20050048027A1/en not_active Abandoned
- 2002-10-31 DK DK02785348T patent/DK1441757T3/da active
- 2002-10-31 SI SI200230745T patent/SI1441757T1/sl unknown
- 2002-10-31 EP EP02785348A patent/EP1441757B1/de not_active Expired - Lifetime
- 2002-10-31 KR KR1020047006691A patent/KR100816221B1/ko not_active IP Right Cessation
- 2002-10-31 CN CNB028234782A patent/CN100446810C/zh not_active Expired - Fee Related
- 2002-10-31 BR BR0213856-5A patent/BR0213856A/pt not_active Application Discontinuation
- 2002-10-31 EP EP10011603A patent/EP2368567A1/de not_active Withdrawn
- 2002-10-31 AT AT08012976T patent/ATE547115T1/de active
- 2002-10-31 EA EA201000386A patent/EA201000386A1/ru unknown
- 2002-10-31 MX MXPA04004155A patent/MXPA04004155A/es active IP Right Grant
- 2002-10-31 PT PT02785348T patent/PT1441757E/pt unknown
- 2002-10-31 HU HU0402165A patent/HU230163B1/hu not_active IP Right Cessation
- 2002-10-31 KR KR1020097025518A patent/KR20090128583A/ko not_active Application Discontinuation
- 2002-10-31 ES ES02785348T patent/ES2311070T3/es not_active Expired - Lifetime
- 2002-10-31 EP EP08012976A patent/EP1997510B1/de not_active Expired - Lifetime
- 2002-10-31 AU AU2002350660A patent/AU2002350660C1/en not_active Ceased
- 2002-10-31 JP JP2003539706A patent/JP5004407B2/ja not_active Expired - Fee Related
- 2002-10-31 NZ NZ545414A patent/NZ545414A/en not_active IP Right Cessation
- 2002-10-31 DK DK08012976.0T patent/DK1997510T3/da active
- 2002-10-31 PT PT08012976T patent/PT1997510E/pt unknown
-
2003
- 2003-11-07 HK HK03108108.9A patent/HK1057328A1/xx not_active IP Right Cessation
-
2004
- 2004-04-30 HR HRP20040383AA patent/HRP20040383B1/xx not_active IP Right Cessation
- 2004-04-30 ZA ZA200403285A patent/ZA200403285B/en unknown
- 2004-06-01 NO NO20042262A patent/NO329789B1/no not_active IP Right Cessation
-
2005
- 2005-12-20 US US11/311,475 patent/US20060142195A1/en not_active Abandoned
-
2008
- 2008-06-27 US US12/163,828 patent/US8071091B2/en not_active Expired - Fee Related
- 2008-08-22 US US12/196,785 patent/US8119597B2/en not_active Expired - Fee Related
- 2008-10-23 CY CY20081101193T patent/CY1108446T1/el unknown
-
2009
- 2009-01-05 JP JP2009000322A patent/JP2009137983A/ja not_active Withdrawn
- 2009-11-19 CY CY20091101206T patent/CY1109648T1/el unknown
-
2010
- 2010-05-11 IL IL205695A patent/IL205695A0/en unknown
-
2012
- 2012-02-10 US US13/370,706 patent/US20130039902A1/en not_active Abandoned
- 2012-04-30 CY CY20121100407T patent/CY1112957T1/el unknown
-
2014
- 2014-01-09 US US14/151,390 patent/US20140199287A1/en not_active Abandoned
-
2016
- 2016-03-24 US US15/079,550 patent/US20170051268A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1108446T1 (el) | Μη νευροτοξικοι παραγοντες ενεργοποιησης πλασμινογονου για την αντιμετωπιση αποπληξιας | |
MY136707A (en) | Thrombopoietin mimetics | |
HK1068811A1 (en) | Substituted oxazolidinones for combinational therapy | |
HRP20050903B1 (hr) | Intravenska injekcija ne-neurotoksiäśnih aktivatora plazminogena za tretman kapi | |
DK1349856T3 (da) | Isoindolin-1-on-glucokinase-aktivatorer | |
EP1381280A4 (en) | VIRAL VECTORS AND USE THEREOF IN THERAPEUTIC METHODS | |
MXPA04004306A (es) | Uso de antagonistas del receptor de endotelina para el tratamiento de enfermedades tumorales. | |
IL158738A0 (en) | Novel use of 2-phenyl-substituted imidazotriazinones | |
GB0020504D0 (en) | Therapeutic method | |
HK1092045A1 (en) | Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke | |
IL158186A0 (en) | Pharmaceutically active compounds and methods of use | |
MXPA03008406A (es) | Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos y agentes antagonistas de endotelina. | |
MXPA03006742A (es) | Uso de buprenorfina para la terapia de la incontinencia urinaria. | |
PL375354A1 (en) | Use of treosulfan and derivatives thereof for treating multiple sclerosis | |
WO2001079430A3 (fr) | Nouveau polypeptide, serine protease humaine 9, et polynucleotide codant pour ce polypeptide | |
WO2003059334A3 (en) | Gemcitabine in the treatment of smallpox | |
UA33498A (uk) | Спосіб лікування терапевтично резистентних форм шизофренії | |
WO2001075030A3 (fr) | Nouveau polypeptide, tyrosinase humaine 11, et polynucleotide codant pour ce polypeptide | |
GB0031196D0 (en) | Recombinant human plasminogen and plasmin: methods for high yield production stabilization and use for treatment | |
WO2001079432A3 (fr) | Nouveau polypeptide, facteur humain de transcription de la differentiation cellulaire 58, et polynucleotide codant pour ce polypeptide | |
JO2238B1 (en) | Glycine stimulants iswindline 1- on | |
WO2001083758A3 (fr) | Nouveau polypeptide, dihydroorotase humaine 8, et polynucleotide codant pour ce polypeptide | |
WO2001075038A3 (fr) | Nouveau polypeptide, serine hydrolase humaine 9 atp-dependante, et polynucleotide codant pour ce polypeptide | |
WO2001083680A3 (fr) | Nouveau polypeptide, glycinamide ribonucleotide synthetase humaine 11, et polynucleotide codant pour ce polypeptide |